Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials

References

• Wild S Roglic G Green A Sicree R King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27 5 1047 1053 15111519
   PubMed Web of Science ®Google Scholar
• Ren CJ Zhang Y Cui WZ Mu ZM Progress in the role of oxidative stress in the pathogenesis of type 2 diabetes Sheng Li Xue Bao 2013 65 6 664 673 Chinese 24343725
   PubMedGoogle Scholar
• Bogaert YE Schrier RW Into the future: prevention of diabetes Contrib Nephrol 2011 170 256 263 21659778
   PubMed Web of Science ®Google Scholar
• Zenari L Marangoni A What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? Diabetes Obes Metab 2013 15 Suppl 2 17 25 24034516
   PubMed Web of Science ®Google Scholar
• McGill JB Pharmacotherapy in type 2 diabetes: a functional schema for drug classification Curr Diabetes Rev 2012 8 4 257 267 22515702
   PubMedGoogle Scholar
• Gallwitz B Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes Drugs Today (Barc) 2007 43 1 13 25 17315049
   PubMed Web of Science ®Google Scholar
• Omar B Ahren B Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors Diabetes 2014 63 7 2196 2202 24962916
   PubMed Web of Science ®Google Scholar
• Gallwitz B Therapies for the treatment of type 2 diabetes mellitus based on incretin action Minerva Endocrinol 2006 31 2 133 147 16682937
   PubMedGoogle Scholar
• Aschner P Kipnes MS Lunceford JK Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 2006 29 12 2632 2637 17130196
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Cuddihy RM Hanefeld M Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 2012 35 2 252 258 22210563
   PubMed Web of Science ®Google Scholar
• Begg CB Mazumdar M Operating characteristics of a rank correlation test for publication bias Biometrics 1994 50 4 1088 1101 7786990
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes-2014 Diabetes Care 2014 37 Suppl 1 S14 S80 24357209
   PubMed Web of Science ®Google Scholar
• World Health Organization Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: report of a WHO consultation Geneva World Health Organization 1999 Available from: http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf Accessed October 3, 2014
   Google Scholar
• Jadad AR Moore RA Carroll D Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 1 1 12 8721797
   PubMedGoogle Scholar
• Sweeting MJ Sutton AJ Lambert PC What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data Stat Med 2004 23 9 1351 1375 15116347
   PubMed Web of Science ®Google Scholar
• Zintzaras E Ioannidis JP Heterogeneity testing in meta-analysis of genome searches Genet Epidemiol 2005 28 2 123 137 15593093
   PubMed Web of Science ®Google Scholar
• Egger M Davey Smith G Schneider M Minder C Bias in meta-analysis detected by a simple, graphical test BMJ 1997 315 7109 629 634 9310563
   PubMed Web of Science ®Google Scholar
• Maindonald J Braun WJ Data Analysis and Graphics Using R: An Example-Based Approach 3rd ed New York Cambridge University Press 2010
   Google Scholar
• Charbonnel B Karasik A Liu J Wu M Meininger G Sitagliptin Study 020 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 2006 29 12 2638 2643 17130197
   PubMed Web of Science ®Google Scholar
• Chan JCN Scott R Arjona Ferreira JC Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Diabetes Obes Metab 2008 10 7 545 555 18518892
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Johnson J Teng R Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study Curr Med Res Opin 2009 25 3 569 583 19232032
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Johnson J Teng R Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes Diabetes Obes Metab 2010 12 5 442 451 20415693
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Forti A Chiasson J-L Woloschak M Boldrin M Balena R Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial) Diabetes Ther 2012 3 1 13 23138449
   PubMedGoogle Scholar
• Dobs AS Goldstein BJ Aschner P Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes J Diabetes 2013 5 1 68 79 22742523
   PubMed Web of Science ®Google Scholar
• Schernthaner G Gross JL Rosenstock J Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 2013 36 9 2508 2515 23564919
   PubMed Web of Science ®Google Scholar
• Rosenstock J Brazg R Andryuk PJ Lu K Stein P Sitagliptin Study 019 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2006 28 10 1556 1568 17157112
   PubMed Web of Science ®Google Scholar
• Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams-Herman DE Sitagliptin 036 Study Group Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 8 1979 1987 17485570
   PubMed Web of Science ®Google Scholar
• Scott R Wu M Sanchez M Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract 2007 61 1 171 180 17156104
   PubMed Web of Science ®Google Scholar
• Raz I Chen Y Wu M Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Curr Med Res Opin 2008 24 2 537 550 18194595
   PubMed Web of Science ®Google Scholar
• Aschner P Katzeff HL Guo H Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes Diabetes Obes Metab 2010 12 3 252 261 20070351
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Wysham C Macconell L Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2010 376 9739 431 439 20580422
   PubMed Web of Science ®Google Scholar
• Barzilai N Guo H Mahoney EM Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial Curr Med Res Opin 2011 27 5 1049 1058 21428727
   PubMed Web of Science ®Google Scholar
• Aschner P Chan J Owens DR Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial Lancet 2012 379 9833 2262 2269 22683131
   PubMed Web of Science ®Google Scholar
• Yang W Guan Y Shentu Y The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes J Diabetes 2012 4 3 227 237 22672586
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Corry D Mogensen CE Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial Am J Kidney Dis 2013 61 4 579 587 23352379
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Marre M Barzilai N Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 2013 36 5 1067 1073 23248197
   PubMed Web of Science ®Google Scholar
• Raz I Hanefeld M Xu L Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 2006 49 11 2564 2571 17001471
   PubMed Web of Science ®Google Scholar
• Hermansen K Kipnes M Luo E Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabetes Obes Metab 2007 9 5 733 745 17593236
   PubMed Web of Science ®Google Scholar
• Mohan V Yang W Son H-Y Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea Diabetes Res Clin Pract 2009 83 1 106 116 19097665
   PubMed Web of Science ®Google Scholar
• Chien M-N Lee C-C Chen W-C Liu S-C Leung C-H Wang C-H Effect of sitagliptin as add-on therapy in elderly type 2 diabetes patients with inadequate glycemic control in Taiwan Int J Gerontol 2011 5 2 103 106
   Web of Science ®Google Scholar
• Pratley R Nauck M Bailey T One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Int J Clin Pract 2011 65 4 397 407 21355967
   PubMed Web of Science ®Google Scholar
• Rosenstock J Aggarwal N Polidori D Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 2012 35 6 1232 1238 22492586
   PubMed Web of Science ®Google Scholar
• Kobayashi K Yokoh H Sato Y Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial Diabetes Obes Metab 2014 16 8 761 765 24447683
   PubMed Web of Science ®Google Scholar
• Moher D Liberati A Tetzlaff J Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int J Surg 2010 8 5 336 341 20171303
   PubMed Web of Science ®Google Scholar
• Scott R Loeys T Davies MJ Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab 2008 10 10 959 969 18201203
   PubMed Web of Science ®Google Scholar
• Wu D Li L Liu C Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis Diabetes Obes Metab 2014 16 1 30 37 23803146
   PubMed Web of Science ®Google Scholar
• Argyrakopoulou G Doupis J DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy Adv Ther 2009 26 3 272 280 19259628
   PubMed Web of Science ®Google Scholar
• Hanefeld M Herman GA Wu M Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes Curr Med Res Opin 2007 23 6 1329 1339 17559733
   PubMed Web of Science ®Google Scholar
• Scott R Wu M Sanchez M Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract 2007 61 1 171 180 17156104
   PubMed Web of Science ®Google Scholar
• Oh JH Choi MG Kang MI The prevalence of gastrointestinal symptoms in patients with non-insulin dependent diabetes mellitus Korean J Intern Med 2009 24 4 309 317 19949728
   PubMedGoogle Scholar
• Bytzer P Talley NJ Leemon M Young LJ Jones MP Horowitz M Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults Arch Intern Med 2001 161 16 1989 1996 11525701
   PubMedGoogle Scholar
• Nakamura T Suda T Kon M Pathophysiology and treatment of diabetic diarrhea J Smooth Muscle Res 1996 32 2 27 42 8845564
   PubMedGoogle Scholar
• Mei Q Mundinger TO Lernmark A Taborsky GJ Early, selective, and marked loss of sympathetic nerves from the islets of biobreeder diabetic rats Diabetes 2002 51 10 2997 3002 12351439
   PubMed Web of Science ®Google Scholar
• Johnson AB Webster JM Sum CF The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients Metabolism 1993 42 9 1217 1222 8412779
   PubMed Web of Science ®Google Scholar
• Perriello G Misericordia P Volpi E Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production Diabetes 1994 43 7 920 928 8013758
   PubMed Web of Science ®Google Scholar
• Jabbour S Ziring B Advantages of extended-release metformin in patients with type 2 diabetes mellitus Postgrad Med 2011 123 1 15 23 21293080
   PubMed Web of Science ®Google Scholar
• Zolk O Disposition of metformin: variability due to polymorphisms of organic cation transporters Ann Med 2012 44 2 119 129 21366511
   PubMed Web of Science ®Google Scholar
• Padwal RS Gabr RQ Sharma AM Effect of gastric bypass surgery on the absorption and bioavailability of metformin Diabetes Care 2011 34 6 1295 1300 21478461
   PubMed Web of Science ®Google Scholar
• Gould M Sellin JH Diabetic diarrhea Curr Gastroenterol Rep 2009 11 5 354 359 19765362
   PubMedGoogle Scholar
• Bouchoucha M Uzzan B Cohen R Metformin and digestive disorders Diabetes Metab 2011 37 2 90 96 21236717
   PubMed Web of Science ®Google Scholar
• Lavalle-Gonzalez FJ Januszewicz A Davidson J Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 2013 56 12 2582 2592 24026211
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01076088?term=NCT01076088&rank=1. NLM identifier: NCT 01076088 Accessed October 23, 2014
   Google Scholar
• Merck Sharp & Dohme Corp A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00411554?term=00411554&rank=1. NLM identifier: NCT 00411554 Accessed October 23, 2014
   Google Scholar
• Merck Sharp & Dohme Corp An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) Available from: http://www.clinicaltrials.gov/ct2/show/NCT00094770?term=NCT00094770&rank=1. NLM identifier: NCT 00094770 Accessed October 23, 2014
   Google Scholar